Abstract Library

#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1

Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: bai J

Authors: Bai J, Tang Q,

Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,

#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,

Keywords: CgA, PRRT, prognosis,

#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy

Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Aalbersberg E, Versleijen M, Tesselaar M, Walraven I,

Keywords: PRRT, RECIST, 68Ga-DOTATATE PET/CT, response,

#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results

Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,

Keywords: neuroendocrine tumours, lanreotide, biomarkers,

#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B,

Keywords: pancreatic neuroendocrine tumors, biomarkers, chromogranin A, vasostatin 1, recurrence,